On the other hand, immunologically “hot” tumors such as melanoma, head and neck, and lung [58], that are generally more sensitive to immune checkpoint blockade may also benefit from TransCon TLR7/8 Agonist through further potentiation of antigen presentation and of induction of local inflammation. Here, TLR7 is linked to melanoma.